Fraunhofer Project Group starting in BioPark Regensburg
The location of the Fraunhofer Project Group at BioPark Regensburg strongly believes that external university research institutes attach importance to dialogue with the University. By working together it is not seldom that innovative research for the future grows. The goal of the 25 employees in the project group is the further development of innovative therapeutic processes for the treatment of liver and lung tumours and new diagnostic markers of metabolic illnesses/tumours. Under the leadership of the Managing Director Prof. Borlak integrated methods of functional proteome and genome research are used in the Fraunhofer Project Group to validate therapeutic and diagnostic targets in cell biology models and in genetically altered disease models. The acquisition and characterisation of tumour stem cells is a crucial area. A further specialised area for research is the development and characterisation of new therapeutic processes and therapeutic antibodies, which by means of nanoparticles should take effect exactly reaching the goal of where the tumour is occurring. The close collaboration between Hanover and the professorial chair for Clinical Chemistry and Laboratory Medicine at University of Regensburg (Prof. Schmitz) is enabling the rapid development and introduction to the market of innovative treatment processes, including the use of the competences of the Fraunhofer Society, in particular with affiliation to Life Science.
For more information see: